Transcatheter Technologies GmbH, a medical device company that has developed a full range of transcatheter valve implantation systems for catheter-based heart valve therapy, announced today that it has sold its technology portfolio to Venus Medtech. The Transcatheter Technologies’ technology will be the basis of a next generation product portfolio developed and marketed by Venus Medtech for the Chinese and international markets.
Under the agreement, Transcatheter Technologies’ co-founders, CEO and cardiac surgeon Dr. Wolfgang Goetz, M.D., and CTO and engineer Hou-Sen Lim will assist Venus Medtech with the transition and commercialization of the acquired technology for up to three months. Venus Medtech (HangZhou) Inc. develops and manufactures an advanced interventional artificial cardiac valve system. Venus Medtech is a leading heart valve developer in China. Its transcatheter aortic valve has completed clinical trials and follow up, pending China CFDA approval. Its transcatheter pulmonic valve is completing its clinical trials. Both of the valves are expected to be the first transcatheter valves approved in China. They are also developing the next generation heart valves with pre-crimping technology. Venus Medtech sets its goal as a worldwide transcatheter heart valve company. With its clear vision, last month, Venus Medtech announced an investment of $37 million from Goldman Sachs to support R&D and marketing activities for Venus Medtech’s cardiac valve products.
News release can be found from Transcatheter Technologies website following this link.
No comments:
Post a Comment